Multidimensional Palliative Care: Fewer Opioids, More Pain Control in Patients With Advanced Cancer By Chase DoyleDecember 10, 2019 For opioid-tolerant patients with advanced cancer experiencing pain, relief does not necessarily have to come from a higher dose of opioids, according to findings presented at the…
“Although multiple agents targeting PD-1 have been approved as second-line treatment for esophageal squamous cell carcinoma, only a fraction of patients derive long-term survival. Hence,…
The French phase II PANACHE01-PRODIGE48 trial investigated the feasibility and efficacy of neoadjuvant mFOLFIRINOX and FOLFOX in patients with resectable pancreatic adenocarcinoma.
The phase II Neo-N trial investigated the activity of two differing schedules of neoadjuvant nivolumab initiation—lead-in or concurrent—with 12 weeks of carboplatin and paclitaxel in…
Patients with active cancer who developed venous thromboembolism (VTE) and were treated with anticoagulants for at least 6 months, followed by an additional 12 months…
The FDA today approved a dual immunotherapy combination for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
The use of a circulating tumor DNA liquid biopsy to guide colorectal cancer treatment in the adjuvant setting may not compromise outcomes despite allowing many…
In an Italian single-center phase II trial (RADIOSA) reported in The Lancet Oncology, Marvaso et al found that addition of androgen-deprivation therapy (ADT) to stereotactic…
Postmastectomy radiation therapy may be significantly shortened for many patients planning breast reconstruction, according to data from a large phase III trial (RT CHARM, Alliance…
New data from researchers at The University of Texas MD Anderson Cancer Center explored whether surgery is necessary for patients with early-stage breast cancer who…
Guest Editor’s Note: Several epidemiologic studies have shown an inverse association between healthy dietary patterns and the risk of chronic diseases including cancer. Patients are…
